ライフサイエンスコーパス: isoproterenol

1 B-transduced hES2-vCMs uniquely responded to isoproterenol.

2 f contraction or procontractile signaling by isoproterenol.

3 of 100 Hz) or weak stimulation augmented by isoproterenol.

4 ine and in additional 16 of 44 (36.4%) after isoproterenol.

5 gnature for all of the compounds relative to isoproterenol.

6 ls observed in vivo, cells were treated with isoproterenol.

7 in the absence or in the presence of 125 nM isoproterenol.

8 0.01) but a preserved heart-rate response to isoproterenol.

9 oncentrations of the beta-adrenergic agonist isoproterenol.

10 rdiac hypertrophy, we stressed the mice with isoproterenol.

11 ells pretreated with beta-adrenergic agonist isoproterenol.

12 left ventricular myocytes in the presence of isoproterenol.

13 thermia group had a higher force response to isoproterenol.

14 ed the cardiac beta1-AR signaling pathway to isoproterenol.

15 stimulation with the beta-adrenergic agonist isoproterenol.

16 lowing deactivation, similar to perfusion of isoproterenol.

17 h slower than that induced by betaAR agonist isoproterenol.

18 in CR to about half of the level produced by isoproterenol.

19 re-elevated with the beta-adrenergic agonist isoproterenol.

20 t baseline and following a 7-day infusion of isoproterenol.

21 tenuation of glycerol release in response to isoproterenol.

22 vely prevented triggered activity induced by isoproterenol.

23 use hearts during inotropic stimulation with isoproterenol.

24 omparable to that seen in WT VM treated with isoproterenol.

25 r metoprolol and the beta-adrenergic agonist isoproterenol.

26 opic response to the beta-adrenergic agonist isoproterenol.

27 cruitment of arrestin to beta2AR relative to isoproterenol.

28 gher beat rate and contractility response to isoproterenol.

29 itoneally injected by saline, propranolol or isoproterenol.

30 ization, although it was reduced relative to isoproterenol.

31 We found that beta-AR stimulation with isoproterenol (0.1 muM) decreased the mitochondrial redo

32 aticity) in the presence of the beta-agonist isoproterenol (0.1 mum; ISO), from 0% to 64% (P < 0.05).

33 o elevated extracellular Ca (2.7 mmol/L) and isoproterenol (0.25 mumol/L) to induce diastolic Ca wave

34 ested by dosing rats with the cardiotoxicant isoproterenol (0.5mg/kg), and a 2-fold decrease in urina

35 imulation (acetylcholine [0.1 micromol/L] or isoproterenol [0.01-0.1 micromol/L]) after termination o

36 fused for 5 minutes with the beta-AR agonist isoproterenol (1 micromol/L) or the blockers CGP+ICI (ba

37 Adrenergic stimulation by isoproterenol (1 muM) or forskolin (5 muM) increased the

38 incubated in primary culture and exposed to isoproterenol (1 mumol/L) or vehicle for 30 hours.

39 Acetylcholine (1 mumol/L), isoproterenol (1 mumol/L), high calcium ([Ca(2+)](o)=5.4

40 Bolus infusions of saline and isoproterenol (1 or 2 mug) were administered in a blinde

41 either the beta-adrenergic receptor agonist isoproterenol (10 mug or 30 mug) or vehicle (Experiment

42 by the cAMP-elevating agonists, forskolin or isoproterenol (10 muM) and by the Ca(2+)-elevating agoni

43 rrent at nearly saturating concentrations of isoproterenol (100 nM) were also significantly reduced,

44 ng was performed with continuous infusion of isoproterenol (45 mug/min) for 3 minutes.

45 eas S1PR1 downregulation can be triggered by isoproterenol (a beta-adrenergic receptor agonist) treat

46 iety in response to intravenous infusions of isoproterenol, a beta-adrenergic agonist similar to adre

47 L2 is upregulated in mouse hearts exposed to isoproterenol, a beta-adrenergic agonist, and isoprotere

48 the presence of the beta-adrenergic agonist isoproterenol, a combination that induced L-LTP, and act

49 eriences following bolus infusions of either isoproterenol, a rapidly acting peripheral beta-adrenerg

50 We used isoproterenol, a rapidly acting peripheral beta-adrenerg

51 phosphorylation of ryanodine receptors under isoproterenol administration in Nod1(-/-)-PMI mice.

52 ac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction.

53 ical and secretory manifestations induced by isoproterenol administration.

54 icular arrhythmias and lower mortality after isoproterenol administration.

55 opranolol administration and increased after isoproterenol administration.

56 Surprisingly, while isoproterenol alone elevated Akt activity, it failed to

57 Isoproterenol also blocked ERK downstream of phorbol 12-

58 terase inhibitor isobutylmethylxanthine, and isoproterenol also significantly increased Rap1-GTP in r

59 Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skel

60 otein-ligand interactions for two compounds, Isoproterenol and 5-fluorouridine, highlighted as supero

61 ice also showed reduced inotropic effects of isoproterenol and a reduced tendency for arrhythmias fol

62 ion but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated dese

63 abrogated cardiac hypertrophy in response to isoproterenol and angiotensin II infusion but not pressu

64 ne, insulin-like growth factor-1 (IGF-1), or isoproterenol and assessed for development of hypertroph

65 Treatment with isoproterenol and caffeine in this mouse model resulted

66 as been shown to slow SANC rate responses to isoproterenol and decrease SR Ca(2+) content.

67 The combination of isoproterenol and fMRI offers a powerful approach for ev

68 Isoproterenol and forskolin blocked MEK phosphorylation,

69 2+) channels were appropriately regulated by isoproterenol and forskolin.

70 ciation-6 (INCA6) prevented IKs reduction by isoproterenol and INCA6 suppressed isoproterenol-induced

71 oduced in the presence of the betaAR agonist isoproterenol and intracellular calcium.

72 imal response elicited by the betaAR agonist isoproterenol and its potency in a cAMP accumulation ass

73 ound that the phosphorylation of PREX1 after isoproterenol and prostaglandin E2-mediated GPCR activat

74 Compared with baseline in AF patients, isoproterenol and rapid pacing decreased activation late

75 amically diverse beta-adrenoceptor agonists, isoproterenol and salmeterol.

76 Although isoproterenol and stepwise increases in stimulation freq

77 ion is a common pathway for AF initiation by isoproterenol and tachycardia via reduced activation lat

78 ria expression in osteoblasts, regulation by isoproterenol, and ability to trap the insulin receptor

79 ylcholinesterase (AChE) with metaproterenol, isoproterenol, and newly synthesized racemic bisdimethyl

80 the SR induced by a beta-adrenergic agonist, isoproterenol, and subsequently blocks isoproterenol-ind

81 affinity catecholamine agonist hydroxybenzyl isoproterenol, and the low-affinity endogenous agonist a

82 bited arrhythmic contractions in response to isoproterenol, and up to 20% of STAA cells failed to sus

83 larly, Epac1 KO animals showed resistance to isoproterenol- and aging-induced cardiomyopathy and atte

84 gh an oxidation-dependent mechanism, whereas isoproterenol- and phenylephrine-mediated mechanisms had

85 Metaproterenol and isoproterenol are bronchodilators that provide a structu

86 Using the beta-adrenergic agonist isoproterenol as a specific pathological stressor to cir

87 duced MCCV-increases induced by forskolin or isoproterenol but not increases induced by carbachol.

88 nse to 10 muM of the beta-adrenergic agonist isoproterenol (by 42%), 10 muM of the adenyl cyclase act

89 Accordingly, in the presence of isoproterenol, Ca(2+) transients and contraction amplitu

90 found that treatment with the beta-AR agent isoproterenol caused substantial LD loss via activation

91 Isoproterenol caused the appearance of spontaneous Ca(2+

92 all Ca(2+)-sensitized hearts, in vivo after isoproterenol challenge and in isolated hearts after rap

93 We used pressure-volume relationships and isoproterenol challenge to assess the effect of recombin

94 e of recurrent arrhythmia >1 year, high-dose isoproterenol challenge was used to disclose non-PV trig

95 Isoproterenol challenge yielded additional 36.4% of thos

96 Electrocardiography on isoproterenol challenged mice showed that both models de

97 fibrosis and inflammation in aged as well as isoproterenol-challenged heart than age-matched wild typ

98 he beta-adrenergic receptor (betaAR) agonist isoproterenol, consistent with the immunoelectron micros

99 Unlike isoproterenol, CXL-1020 was equally effective in myocyte

100 armacological inhibition of MMP-13 prevented isoproterenol-dependent cardiac dysfunction in mice.

101 This isoproterenol-dependent cleavage was significantly reduc

102 Oxidative stress induced by chronic isoproterenol, detected by 8-OhDG was 15% greater, P=0.0

103 Isoproterenol did not induce LDCAE in the presence of ry

104 4(-/-) mice with the beta-adrenergic agonist isoproterenol did not trigger ventricular arrhythmia but

105 cle strips from Tg-CTGF mice stimulated with isoproterenol displayed attenuation of maximal inotropic

106 Isoproterenol dramatically increased the frequency of Ca

107 (EC50 1.8 mM) and verapamil (IC50 0.61 muM); isoproterenol elicited a positive chronotropic but negli

108 Isoproterenol elicited dose-dependent increases in cardi

109 tion with the inotropic and lusitropic agent isoproterenol eliminated the differences among wild-type

110 Notably, in native parotid cells isoproterenol enhanced the carbachol-promoted increases

111 induction by programmed stimulation without isoproterenol, entrainment in some, and abnormal electro

112 cells, yielded a wider release source in the isoproterenol event, indicating the recruitment of perip

113 1C myocytes from older mice are treated with isoproterenol, evidence of excitation-contraction uncoup

114 osteoclast hyperfunction while beta-agonist (isoproterenol) exacerbated those responses.

115 Sustained isoproterenol exposure decreased IKs density (whole cell

116 ecreased IKs density to an extent similar to isoproterenol exposure, and adenoviral-mediated knockdow

117 A inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibr

118 In cardiac-specific Bin1 heterozygote mice, isoproterenol fails to concentrate BIN1 to t-tubules, im

119 ive isoproterenol group than in the negative isoproterenol group (P<0.0001, exact log-rank test).

120 osis was significantly lower in the positive isoproterenol group than in the negative isoproterenol g

121 culture with or without IL-13 (48 hours) or isoproterenol hydrochloride (ISO; 30 minutes) pretreatme

122 mained unchanged, and activation of PKA with isoproterenol improved cardiac contractility.

123 n determined the electrophoretic mobility of isoproterenol in a high ion solution to be -7 x 10(-9) m

124 amined the cardiomyopathy induced by chronic isoproterenol in AC5 transgenic (Tg) mice and the signal

125 SR Ca(2+) content and SANC rate responses to isoproterenol in mice with AC3-I expression, suggesting

126 mpanying action potentials were increased by isoproterenol in myocytes from WT mice, but these effect

127 ated response to subsequent stimulation with isoproterenol, including decreased cAMP levels, PKA acti

128 e variability and fractal behavior, and that isoproterenol increased and carbamylcholine decreased th

129 Chronic isoproterenol increased oxidative stress and induced mor

130 Isoproterenol increases (+57%) and acetylcholine decreas

131 n leads to a decrease in expression, whereas isoproterenol increases expression in WAT.

132 mulation of wild-type EPCs with beta-agonist isoproterenol induced a significant increase of Flk-1 ex

133 Interestingly, isoproterenol induced CD36 internalization, and this pro

134 Isoproterenol induced global decreases in methylation in

135 e, we found that the beta-adrenergic agonist isoproterenol induced mature beta-adrenergic signaling i

136 Isoproterenol induced nuclear NFATc3/c4 translocation (i

137 lphas-coupled beta-adrenergic receptors with isoproterenol induced PKA-dependent activation of endoge

138 ly, proximity ligation assays indicated that isoproterenol induced PKA-dependent phosphorylation of e

139 , NAADP antagonist BZ194 largely ameliorated isoproterenol-induced arrhythmias in awake mice.

140 CD38 in docking simulations and reduced the isoproterenol-induced arrhythmias in WT hearts.

141 ion of intracellular calcium homeostasis and isoproterenol-induced arrhythmias that are prevented by

142 ed marked defects in both PKA activation and isoproterenol-induced ATGL translocation to the LD perip

143 nd DAD-induced triggered activity as well as isoproterenol-induced automaticity elicited in SVC sleev

144 Although isoproterenol-induced cAMP response was not prolonged by

145 n of Abcc6 dramatically and rapidly promotes isoproterenol-induced cardiac fibrosis.

146 exhaustive exercises and less susceptible to isoproterenol-induced cardiac hypertrophy at both young

147 fied an inhibitory effect of UDP on in vitro isoproterenol-induced cardiomyocyte hyperplasia and hype

148 differentiation stimuli, sensitizing CPC to isoproterenol-induced cell death that is abrogated by me

149 ore, AAV9-miRYR2-U10 effectively (1) reduced isoproterenol-induced delayed afterdepolarizations and t

150 f mice that are susceptible and resistant to isoproterenol-induced dysfunction to test the hypothesis

151 Finally, isoproterenol-induced GRK2 phosphorylation enhanced CAV1

152 etermined to be susceptible and resistant to isoproterenol-induced heart failure, respectively, were

153 In the isoproterenol-induced hypertrophic mouse model, we show

154 wed an impaired capacity to adapt to stress (isoproterenol-induced hypertrophy), likely because of de

155 panol dihydrochloride (CGP-20712A) prevented isoproterenol-induced IKs downregulation, whereas the be

156 oviral-mediated knockdown of Epac1 prevented isoproterenol-induced IKs/KCNE1 downregulation.

157 mal function with bafilomycin A1 reduced the isoproterenol-induced increase in Ca(2+) transients in c

158 Isoproterenol-induced increase in Rap1 activity was inhi

159 soproterenol, a beta-adrenergic agonist, and isoproterenol-induced increases in the NFAT target genes

160 uction by isoproterenol and INCA6 suppressed isoproterenol-induced KCNE1 downregulation, consistent w

161 th 1,25-dihydroxyvitamin D partially reduced isoproterenol-induced MCIP1 mRNA and protein levels and

162 eta-adrenergic signaling and is required for isoproterenol-induced myocardial hypertrophy.

163 ly modified the time course and the level of isoproterenol-induced phosphorylation of vasodilator-sti

164 nist, isoproterenol, and subsequently blocks isoproterenol-induced PKA phosphorylation of phospholamb

165 the Kv7 inhibitor linopirdine, and impaired isoproterenol-induced relaxations.

166 cholinergic stimulation completely abolished isoproterenol-induced triggered activity in both dyssync

167 and release, consistent with the absence of isoproterenol-induced ventricular arrhythmia.

168 ling in response to 2 independent stressors: isoproterenol infusion and an activated calcineurin tran

169 subjected to pressure overload stimulation, isoproterenol infusion, and swimming showed greater card

170 subjected to thoracic aortic constriction or isoproterenol infusion.

171 PVCs in all the VTs induced during high-dose isoproterenol infusion.

172 of which 16 (59%) occurred during high-dose isoproterenol infusion.

173 d by transverse aortic constriction (TAC) or isoproterenol infusion.

174 Isoproterenol infusions induced anxiety in both patients

175 is recognized using pacing maneuvers and/or isoproterenol infusions.

176 SAN automaticity in RyR2(R4496C) mice after isoproterenol injection, analogous to what was observed

177 taneously as assessed by ECG telemetry after isoproterenol injection.

178 thological cardiac hypertrophy induced after isoproterenol injection.

179 Here, we applied isoproterenol into these surface openings by changing th

180 myocytes stimulated with the beta-AR agonist isoproterenol (ISO) (anxA4a(+/+) vs. anxA4a(-/-): 5.1 +/

181 centrations of the beta-adrenoceptor agonist isoproterenol (ISO) and by varying afterload pressures.

182 nduced in the adult feline heart by infusing isoproterenol (ISO) for 10 days via minipumps, and then

183 served that chronic beta-AR stimulation with isoproterenol (ISO) for 48 h reduced Ito,f along with mR

184 sceptibility of cardiac damage responding to isoproterenol (ISO) in adult offspring that underwent ma

185 Isoproterenol (ISO) increased Ca2+ transient amplitude d

186 uced in wild-type and IL-10 knockout mice by isoproterenol (ISO) infusion.

187 The effects of the PKA activator Isoproterenol (Iso) on L-type Ca(2+) current (I(CaL)), c

188 compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II).

189 Isoproterenol (ISO) or PKA activation results in strong

190 Here, we show that chronic administration of isoproterenol (ISO) persistently increases the frequency

191 stimulation of beta-adrenergic receptors by isoproterenol (ISO) resulted in an impaired contractile

192 es measured under basal conditions and after isoproterenol (Iso) stimulation.

193 lar ejection fraction after stimulation with isoproterenol (ISO), a beta-adrenergic receptor (betaAR)

194 ) followed by the beta-adrenoceptor agonist, isoproterenol (ISO), or the beta-adrenoceptor antagonist

195 to multiple hypertrophic stimuli, including isoproterenol (ISO), phenylephrine (PE), and endothelin-

196 with high glucose (HG) and the beta-agonist isoproterenol (ISO).

197 The beta-adrenergic agonist isoproterenol (ISO; 1 muM) increased [Ca(2+)](SR) well a

198 ated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg) in mice causes acute myoc

199 derivatives of metaproterenol (metacarb) and isoproterenol (isocarb) and their (R)-enantiomers to see

200 itions: (1) beta-adrenergic stimulation with isoproterenol (isoprenaline) accelerated spark amplitude

201 itions: (1) beta-adrenergic stimulation with isoproterenol (isoprenaline) accelerated spark amplitude

202 ild-type mice with the beta-receptor agonist isoproterenol (isoprenaline) increased RyR1 PKA phosphor

203 t was combined with a cAMP-mediated agonist (isoproterenol (isoprenaline) or vasoactive intestinal pe

204 young postnatal cardiomyocytes responded to isoproterenol (isoprenaline) with a decrease in cell siz

205 vity (beta-adrenergic stimulation with 1 muM isoproterenol (isoprenaline)) decreased the latency peri

206 t on the CR was determined by application of isoproterenol (isoprenaline).

207 Isoproterenol (isoprenaline; betaAR agonist) dilated 1A,

208 However, in the presence of isoproterenol, leak produced a biphasic decay of the Ca

209 Exposure to isoproterenol led to phosphorylation of PDE3A1 at the 14

210 This reduced response to isoproterenol may be attributable to the lower cAMP sens

211 These findings suggest that dopamine and isoproterenol may enhance CRF release from local BNST so

212 I (CaMKII), the inhibition of which prevents isoproterenol-mediated and Ang II-mediated cardiomyopath

213 quent rescue by isoproterenol and additional isoproterenol-mediated desensitization.

214 Moreover, isoproterenol-mediated increase in contraction rate, sur

215 o increased PDE4D expression causing reduced isoproterenol-mediated phosphorylation of cTnI and PLN.

216 prevent LDCAE or AVJ acceleration induced by isoproterenol (n = 2).

217 Isoproterenol (n=14), adenosine (n=10), or rapid pacing

218 de enhanced the effect of the bronchodilator isoproterenol on airway relaxation.

219 release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium

220 The effects of isoproterenol on relaxation velocity, left ventricular s

221 PKA inhibitor Rp-cAMPS blocks the effects of isoproterenol on the nuclear influx of HDAC4-GFP, and Rp

222 During beta-adrenergic stimulation (100 nM isoproterenol), only Casq2(-/-) atrial myocytes showed p

223 tivation of PKA by the beta-receptor agonist isoproterenol or dibutyryl (Db) cAMP causes a steady HDA

224 n of hormone sensitive lipase in response to isoproterenol or forskolin.

225 ent, or G protein-coupled receptor agonists (isoproterenol or parathyroid hormone (PTH)(1-34)).

226 Cholera toxin treatment or agonist (isoproterenol or pituitary adenylate cyclase activating

227 arget sites failed to affect HR responses to isoproterenol or spontaneous activity in vivo or in SANC

228 ate and SAN cell automaticity in response to isoproterenol or the dihydropyridine Ca(2+) channel agon

229 agonizing the smooth muscle contraction with isoproterenol, or by blocking myosin light chain kinase

230 n contrast, we show that when application of isoproterenol precedes application of NMDA by several mi

231 rs exposed to the LTCC agonists BayK8644 and isoproterenol produce EAD bursts that are suppressed by

232 Isoproterenol redistributes BIN1 to t-tubules, recruitin

233 In control, isoproterenol reduced I(K1) amplitude by approximately 7

234 o either epinephrine or the beta-AR agonist, isoproterenol, reduced migratory speed and decreased in

235 mplitude of L-type Ca(2+) currents evoked by isoproterenol remained unchanged in myocytes from Tpcn2(

236 Using an isoproterenol rescue protocol after either short-term (1

237 n of LQT2 cells with beta-adrenergic agonist isoproterenol resulted in prolongation of the plateau of

238 e subjected to chronic exposure (14 days) to isoproterenol revealed blunted myocardial hypertrophy an

239 y and Western blotting, we demonstrated that isoproterenol, S-propranolol, CGP-12177 [4-[3-[(1,1-dime

240 ry vein triggers disclosed by high dosage of isoproterenol seems to be of utmost importance to achiev

241 from Tpcn2(-/-) mice chronically exposed to isoproterenol showed less cardiac hypertrophy and increa

242 isolated from CD38(-/-) mice and exposed to isoproterenol showed reduced arrhythmias.

243 21C mice demonstrate that in the presence of isoproterenol, significant delays in Ca(2+) decay and sa

244 Thirty micrograms of the agonist isoproterenol significantly decreased number of attacks

245 is approach, we found that both dopamine and isoproterenol significantly depolarized BNST CRF neurons

246 nse to the administration of a chloride-free isoproterenol solution) from baseline was -3.5 mV (range

247 Computational modeling revealed that isoproterenol steepened APD restitution by increased L-t

248 proliferation increased in diabetic animals: isoproterenol stimulated SGLT1 migration to luminal memb

249 Concentration-response curves of isoproterenol-stimulated cAMP generation in cardiomyocyt

250 amples from AC6-On mice showed increases in: isoproterenol-stimulated cAMP production (p = 0.04), cAM

251 CST did not affect basal or isoproterenol-stimulated cAMP production in adipocytes b

252 RVMs stimulated with conditioned medium from isoproterenol-stimulated cardiac fibroblasts.

253 ere more frequent and had shorter latency in isoproterenol-stimulated cardiomyocytes from RyR2-V2475F

254 ol and Ncx1(-/-) SAN cells under resting and isoproterenol-stimulated conditions.

255 eonine 304, or serine 368 to alanine reduced isoproterenol-stimulated glycerol release in 3T3-L1 adip

256 Conversely, overexpressing PTRF enhanced isoproterenol-stimulated glycerol release.

257 ive AC9 in neonatal cardiomyocytes decreases isoproterenol-stimulated Hsp20 phosphorylation, consiste

258 from endogenous Ca(v)1.2 increased basal and isoproterenol-stimulated L-type Ca(2+) currents in acute

259 mediated glucose uptake, increased basal and isoproterenol-stimulated lipolysis, and decreased adipoc

260 S660, increasing its hydrolase activity and isoproterenol-stimulated lipolysis.

261 reased alkaline phosphatase-PAR1 cleavage in isoproterenol-stimulated NRVMs, as well as in NRVMs stim

262 In isoproterenol-stimulated ventricular myocytes, the RyR2-

263 onditions (DeltaISC 7.1 muA/cm(2)) and after isoproterenol stimulation (increased DeltaISC from 13.9

264 ound that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent

265 Two-week isoproterenol stimulation showed an increase in heart gr

266 in vivo muscle strength responses following isoproterenol stimulation were abrogated in RyR1-S2844A

267 ed Ca2+ transients in cardiac myocytes after isoproterenol stimulation.

268 effectively than in control SAN cells after isoproterenol, suggesting that the importance of NCX cur

269 Ventricular arrhythmogenicity during isoproterenol testing is highly sensitive (sensitivity,

270 positive, and negative predictive values of isoproterenol testing to diagnose ARVC were 91.4%, 88.9%

271 Isoproterenol testing was performed with continuous infu

272 Isoproterenol testing was positive in 32 of 35 (91.4%) p

273 Importantly, initial isoproterenol testing was positive in 6 of 6 (100%) of t

274 2-lead ECG recordings at baseline and during isoproterenol testing.

275 to the CA1, the beta-adrenoreceptor agonist, isoproterenol, the D1/D5 dopaminergic receptor antagonis

276 Treatment of rabbits with isoproterenol to activate beta-adrenergic receptors incr

277 cultured 3T3-L1 adipocytes were treated with isoproterenol to activate lipolysis and the fatty acyl l

278 n inhibits the ability of the betaAR agonist isoproterenol to enhance hippocampal LTP, and this effec

279 Chronic in vivo administration of isoproterenol to guinea pigs reduced IKs density and KCN

280 rats were intranasally treated with saline, isoproterenol (to increase SGLT1 activity) or phlorizin

281 myocytes (NRVMs) or cardiac fibroblasts with isoproterenol transduced with an alkaline phosphatase-ta

282 In isoproterenol-treated DBA/2 mice, there was also a great

283 ypertensive rats and antifibrotic effects in isoproterenol-treated rats.

284 ity and the greater spark width found during isoproterenol treatment may increase the probability of

285 It was found that isoproterenol treatment shifts the spark-frequency-J(lea

286 Furthermore, with isoproterenol treatment, although all 4 groups showed in

287 e basal state between strains and then after isoproterenol treatment.

288 Isoproterenol up to 3 micromol/l increased heart rate to

289 dition, the incremental increase elicited by isoproterenol was abolished in neonatal cardiomyocytes a

290 shift of the If activation curve induced by isoproterenol was attenuated in pregnancy.

291 Chemotaxis to isoproterenol was determined by measuring in vitro perip

292 increase in L-type Ca(2+) current caused by isoproterenol was markedly reduced at physiological leve

293 The inhibitory action of isoproterenol was reproduced by cAMP stimuli (forskolin)

294 ng relaxation of ACh-induced contractions by isoproterenol was significantly left-shifted in the pres

295 esence of a beta-adrenergic receptor agonist isoproterenol, was significantly higher in VF myocytes t

296 These metabolic changes induced by isoproterenol were associated with increased sarcoplasmi

297 nsitizing effect is specific for GIP because isoproterenol, which elevates adipocyte cAMP and activat

298 in RyR2(R4496C) SAN cells in the presence of isoproterenol, which may contribute to stopping the "Ca(

299 tion response to the beta-adrenergic agonist isoproterenol, without affecting endothelin-induced vaso

300 splayed poor affinity for metaproterenol and isoproterenol, yet BChE(UU) had an affinity about five t